Last Week, 3 Biotech Companies Uplisted From OTC To NASDAQ
Last Week, 3 Biotech Companies Uplisted From OTC To NASDAQ. Xenetic Biosciences, Inc. (NASDAQ: XBIO), TapImmune, Inc. (NASDAQ: TPIV), and Diffusion Pharmaceuticals Inc. (NASDAQ: DFFN) all uplisted from various tiers of the OTC Markets to the NASDAQ Capital Market. All three companies are in the biotech/biopharma space.
All of these companies had zero revenue in the quarter prior to uplisting. So far, these are the only companies to leave the OTC Markets for a senior exchange in November.
Xenetic Biosciences, Inc. (NASDAQ: XBIO)
Xenetic Biosciences, Inc. is a clinical-stage biopharmaceutical company focused on discovery, research and development of next-generation biologic drugs and novel oncology therapeutics. Xenetic’s proprietary drug technology platforms include PolyXen®, designed to develop next generation biologic drugs by extending the efficacy, safety and half-life of biologic drugs.
Xenetic Biosciences, Inc. (NASDAQ: XBIO) left the OTCQB for the NASDAQ on November 7th. Immediately prior to uplisting to the NASDAQ, XBIO completed a $1o,ooo,ooo public equity offering where Ladenburg Thalmann & Co. Inc. acted as the sole book running manager.
Terms of the XBIO public offering where as follows: an aggregate of 2,424,242 units, consisting of (i) 484,849 units, consisting of one share of Convertible Series B Preferred Stock and a Class A Warrant to purchase one share of common stock and (ii) 1,939,393 units consisting of one share of Convertible Series B Preferred Stock and a Class B Warrant to purchase one share of common stock, at a public offering price of $4.125 per unit were sold. OPKO Health, Inc. (Nasdaq:OPK) along with other healthcare institutional investors participated in the offering.
TapImmune, Inc. (NASDAQ: TPIV)
TapImmune Inc. is an immuno-oncology company specializing in the development of innovative peptide and gene-based immunotherapeutics and vaccines technologies for the treatment of cancer and metastatic disease. The Company’s peptide or nucleic acid-based immunotherapeutics, comprise one or multiple naturally processed epitopes (NPEs) designed to comprehensively stimulate a patients’ killer T-cells, helper T-cells and to restore or further augment antigen presentation by using proprietary nucleic acid-based expression systems.
TapImmune, Inc. (NASDAQ: TPIV) left the OTC for the NASDAQ on November 8th. TPIV’s last capital infusion took place in September (2016) when the company raised $9,ooo,ooo via the exercise of warrants and a PiPE transaction.
A number of our current investors exercised a total of 12 million warrants, resulting in a $6 million cashinfusion for TapImmune while simultaneously closing on an additional $3 million financing through a PIPE.
Diffusion Pharmaceuticals Inc. (NASDAQ: DFFN)
Diffusion Pharmaceuticals is a clinical stage biotechnology company focused on extending the life expectancy of cancer patients by improving the effectiveness of current standard-of-care treatmentsincluding radiation therapy and chemotherapy. Diffusion is developing its lead drug, trans sodium crocetinate (TSC), for use in the many cancer types in which tumor hypoxia is known to diminish the effectiveness of current treatments.
Diffusion Pharmaceuticals Inc. (NASDAQ: DFFN) left the OTCQX for the NASDAQ on November 9th. DFFN did not close a significant funding prior to uplistng but did merge with a company in January 2016 that resulted in an $8,5oo,oo cash infusion.